Department of Epidemiology, University of Washington, Seattle, WA, USA.
The Comparative Health Outcomes Policy & Economics Institute, University of Washington, Seattle, WA, USA.
J Int AIDS Soc. 2021 Apr;24(4):e25686. doi: 10.1002/jia2.25686.
HIV retesting during late pregnancy and breastfeeding can help detect new maternal infections and prevent mother-to-child HIV transmission (MTCT), but the optimal timing and cost-effectiveness of maternal retesting remain uncertain.
We constructed deterministic models to assess the health and economic impact of maternal HIV retesting on a hypothetical population of pregnant women, following initial testing in pregnancy, on MTCT in four countries: South Africa and Kenya (high/intermediate HIV prevalence), and Colombia and Ukraine (low HIV prevalence). We evaluated six scenarios with varying retesting frequencies from late in antenatal care (ANC) through nine months postpartum. We compared strategies using incremental cost-effectiveness ratios (ICERs) over a 20-year time horizon using country-specific thresholds.
We found maternal retesting once in late ANC with catch-up testing through six weeks postpartum was cost-effective in Kenya (ICER = $166 per DALY averted) and South Africa (ICER=$289 per DALY averted). This strategy prevented 19% (Kenya) and 12% (South Africa) of infant HIV infections. Adding one or two additional retests postpartum provided smaller benefits (1 to 2 percentage point increase in infections averted versus one retest). Adding three retests during the postpartum period averted additional infections (1 to 3 percentage point increase in infections averted versus one retest) but ICERs ($7639 and in Kenya and $11 985 in South Africa) greatly exceeded the cost-effectiveness thresholds. In Colombia and Ukraine, all retesting strategies exceeded the cost-effectiveness threshold and prevented few infant infections (up to 31 and 5 infections, respectively).
In high HIV burden settings with MTCT rates similar to those seen in Kenya and South Africa, HIV retesting once in late ANC, with subsequent intervention, is the most cost-effective strategy for preventing infant HIV infections. In these settings, two HIV retests postpartum marginally reduced MTCT and were less costly than adding three retests. Retesting in low-burden settings with MTCT rates similar to Colombia and Ukraine was not cost-effective at any time point due to very low HIV prevalence and limited breastfeeding.
在妊娠晚期和哺乳期进行 HIV 复查有助于发现新的母婴感染,从而预防母婴 HIV 传播(MTCT),但孕产妇复查的最佳时机和成本效益仍不确定。
我们构建了确定性模型,以评估在初始妊娠检测后,对四个国家(南非和肯尼亚[高/中 HIV 流行率]和哥伦比亚和乌克兰[低 HIV 流行率])孕妇群体进行 HIV 复查对 MTCT 的健康和经济影响。我们评估了从晚期产前保健(ANC)到产后九个月的六种不同复查频率的情况。我们使用国家特定阈值,通过增量成本效益比(ICER)在 20 年时间内比较了这些策略。
我们发现,在肯尼亚(ICER=每例 DALY 避免费用 166 美元)和南非(ICER=每例 DALY 避免费用 289 美元),晚期 ANC 进行一次复查,并在产后 6 周内进行追检,这种策略具有成本效益。这种策略可预防 19%(肯尼亚)和 12%(南非)的婴儿 HIV 感染。在产后期间增加一次或两次额外的复查,只会带来较小的益处(与一次复查相比,可避免感染的比例增加 1 到 2 个百分点)。在产后期间进行三次复查可进一步避免感染(与一次复查相比,可避免感染的比例增加 1 到 3 个百分点),但 ICER(肯尼亚为 7639 美元,南非为 11985 美元)大大超过了成本效益阈值。在哥伦比亚和乌克兰,所有复查策略都超过了成本效益阈值,且只能预防很少的婴儿感染(分别为 31 例和 5 例)。
在 MTCT 率与肯尼亚和南非相似的高 HIV 负担国家,晚期 ANC 进行一次复查,随后进行干预,是预防婴儿 HIV 感染最具成本效益的策略。在这些国家,产后进行两次复查可略微降低 MTCT,且比增加三次复查的成本效益更高。在 MTCT 率与哥伦比亚和乌克兰相似的低 HIV 负担国家,任何时候进行复查都不具有成本效益,因为 HIV 流行率非常低,母乳喂养有限。